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Detecting Somatoform Disorders 
in Primary Care With the PHQ-15
ABSTRACT
PURPOSE Because recognition and management of patients with somatoform 
disorders are diffi cult, we wanted to determine the specifi city, sensitivity, and the 
test-retest reliability of the 15-symptom Patient Health Questionnaire (PHQ-15) 
for detection of somatoform disorders in a high-risk primary care population.
METHODS We studied the performance of the PHQ-15 in comparison with the 
Structured Clinical Interview for the Diagnostic and Statistical Manual-IV Axis I dis-
orders (SCID-I) as a reference standard. From January through September 2006, 
we approached patients for participation. This study was conducted in primary 
care settings in the Netherlands. Patients aged between 18 and 70 years were 
eligible if they belonged to 1 or more of the following groups: (1) patients 
with unexplained somatic complaints, (2) frequent attenders, and (3) patients 
with mental health problems. For the SCID-I interview we invited all patients with 
a PHQ-15 score of 6 or greater and a random sample of 30% of patients with 
a PHQ-15 score of less than 6. The primary study outcomes were the sensitivity 
and specifi city for the validity and the κ coeffi cient for the test-retest reliability.
RESULTS Of 2,147 eligible patients, 906 (42%) participated (mean age 48 years, 
62% female). At a cutoff level of 3 or more severe somatic symptoms during the 
past 4 weeks, sensitivity was 78% and specifi city 71%. The test-retest reliability 
was 0.60.
CONCLUSIONS The PHQ-15 is a valid and moderately reliable questionnaire for the 
detection of patients in a primary care setting at risk for somatoform disorders.
Ann Fam Med 2009;7:232-238. DOI: 10.1370/afm.985.
INTRODUCTION
In primary care 20% to 50% of all patients complaining of physi-cal symptoms can be categorized as having medically unexplained symptoms.1,2 Earlier research shows that the criteria for somatoform 
disorders are met in 10% to 16% of all primary care patients.3-5 Usually, 
the medically unexplained symptoms spontaneously resolve or improve by 
effective management. Sometimes the complaints persist, leading to func-
tional impairment.6
Somatoform disorders are a burden for both patients and family physi-
cians. Patients with these disorders are at risk of overtesting and unneces-
sary treatment,7,8 and the doctor-patient relationship is often difﬁ cult and 
strained.9 It is a challenge for physicians to improve their competence 
in recognizing and managing patients with somatoform disorders, and a 
screening questionnaire for somatoform disorders might be helpful.
We wanted to test a screening questionnaire in a subgroup of patients 
for whom family physicians will most likely use the instrument. Because 
screening for early detection in a high-risk population is a key concept 
in family medicine,10 we opted to screen the following population in the 
context of regular primary care: frequent attenders and patients who were 
identiﬁ ed by their family physicians as having either mental health prob-
lems or unexplained somatic complaints.
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We used the Dutch version of the Patient Health 
Questionnaire (PHQ), a short, self-report version 
of the Primary Care Evaluation of Mental Disorders 
(PRIME-MD).11 The PHQ-15, the somatic symptom 
severity scale of the PHQ, is a self-administered diag-
nostic instrument developed for detection of somato-
form disorders that consists of a list of 15 somatic 
symptoms.11 Those 15 symptoms constitute most of the 
physical complaints in primary care.3
The test characteristics of the PHQ-15 have been 
studied by Kroenke et al.4,12 Increasing scores on 
the PHQ-15 are strongly associated with functional 
impairment, disability, and health care use.12 Kroenke 
at al found a high internal reliability and established 
its construct validity by strong associations with func-
tional status, disability days, and symptom-related 
difﬁ culty.4 Interian et al reproduced the high internal 
reliability and established the convergence of the 
PHQ-15 with the Composite International Diagnostic 
Interview.13 Data on test-retest reliability of the PHQ-
15, however, are still lacking.
We addressed 2 questions: (1) is the PHQ-15 a suit-
able questionnaire for the detection of somatoform dis-
orders in a high-risk primary care population, and (2) 
what is the test-retest reliability of the PHQ-15?
METHODS
We compared the performance of the PHQ-15 with 
that of our reference standard, the Structured Clini-
cal Interview for the Diagnostic and Statistical Manual-IV 
(DSM-IV) Axis I disorders (SCID-I), a diagnostic inter-
view for DSM-IV diagnoses.14 The study was conducted 
in primary care settings in 2 regions in the Netherlands. 
From January through September 2006, we approached 
patients aged between 18 and 70 years to participate. 
The institutional ethics review committees of both cen-
ters approved the study protocol.
Study Population
Our study took place within a project that was 
originally designed for screening for depression in a 
primary care population. We predeﬁ ned 3 groups of 
patients who had a high risk for depression.
Unexplained Somatic Complaints
Patients in the unexplained somatic complaints (USC) 
group had somatic complaints that could not be 
explained by a somatic condition. These complaints had 
to be present for at least 3 months. As it is not possible 
to code unexplained somatic complaints using a stan-
dard classiﬁ cation system, as such the International Classi-
ﬁ cation of Primary Care (ICPC), we asked family physicians 
to identify these patients by checking their appoint-
ment lists for the 4 weeks preceding study allocation 
and selecting patients fulﬁ lling the criterion of having 
an unexplained medical complaint for at least 3 months.
Frequent Attenders 
Patients in the frequent attenders (FA) group had 
attendance rates for primary care in the highest 10% 
according to the method proposed by Howe et al15: the 
10% most frequently consulting women and the 10% 
most frequently attending men in 2 age-groups (18 
to 44 and 45 to 70 years) in the year preceding study 
allocation. This method accounted for differences in 
sex and age among frequently attending patients. We 
used computerized attendance data from all practice 
visits, home visits, and telephone consultations with 
doctors, nurses, and other team members. The highest 
10% was determined separately for each family physi-
cian because of differences in practice styles.
Mental Health Problems
Patients in the mental health problems (MHP) group 
visited their family physicians with a new mental 
health problem up to 3 months before the selec-
tion date. The time frame of 3 months was chosen 
because of the transitory nature of most mental health 
problems. We selected these patients from electronic 
patient databases of the participating family physi-
cians, who were accustomed to coding all diagnoses or 
complaints with the ICPC classiﬁ cation system. Patients 
with a psychological or social reason for encounter or 
with a mental health diagnosis can be classiﬁ ed in the 
P and Z chapters. To identify all patients with possible 
mental health problems, we searched the electronic 
patient database for codes from the P and Z classes 
with the following predeﬁ ned free-text words: anxiety, 
worrying, sadness, stress, feeling down, and insomnia.
Procedure
Family physicians received a list of selected patients 
from which they excluded those suffering from schizo-
phrenia, psychosis, bipolar disorder, serious somatic 
disease, or mental retardation, or having difﬁ culties 
with Dutch or English language. We also excluded 
patients with a diagnosis of depression at baseline.
Next, we mailed all selected patients a letter signed 
by the family physician describing the purpose and 
content of the study and asking for their participation, 
including treatment in a trial setting, together with 
an informed consent form and the screening instru-
ment, the PHQ-15. If patients did not respond within 2 
weeks, a reminder was mailed.
In accordance with earlier studies,16,17 participants 
who completed the PHQ-15 screening questionnaire 
and had 3 or more severe somatic symptoms (scoring 6 
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or higher) were referred to as cases, and those who had 
fewer than 3 severe somatic symptoms were referred to 
as noncases. When we decided to use this cutoff point, 
we had not yet decided to exclude 2 symptoms from 
the ﬁ nal analysis.
To assess the criterion validity of the PHQ-15, we 
invited all case participants and a random 40% of non-
case participants for a SCID-I interview 2 weeks after 
receiving the PHQ-15. To determine the test-retest 
reliability of the PHQ-15, we gave the patients the 
PHQ-15 twice: they were asked to ﬁ ll out the PHQ-15 
at baseline and then 2 weeks later, on the same day as 
the SCID-I interview.
Measurement Instruments
Patient Health Questionnaire-15
The PHQ-15 is a somatic symptom severity scale for 
the purpose of diagnosing somatoform disorders. It 
inquires about 15 somatic symptoms or symptom clus-
ters that account for more than 90% of the physical 
complaints (excluding upper respiratory tract symp-
toms) reported in the outpatient setting. For 13 of the 
somatic symptoms, subjects are asked, “During the past 
4 weeks, how much have you been bothered by any 
of the following problems?” The 3 scoring options are 
coded as 0 (not bothered at all), 1 (bothered a little), or 
2 (bothered a lot). A somatic symptom with the score 
of 2 is considered severe. 
For the 2 somatic symptoms that are also part of 
the PHQ depression module—feeling tired or hav-
ing little energy, and trouble sleeping—subjects are 
asked, “Over the past 2 weeks, how often have you 
been bothered by any of the following problems?” The 
4 scoring options are coded as 0 (not at all), 1 (several 
days), or 2 (more than half the days, or nearly every 
day). A symptom score of 2 is considered to be severe.
According to the original algorithm of the PHQ-
15, in a primary care population the test is considered 
positive when 3 or more severe somatic symptoms 
are present, which is indicated by a test result of 6 or 
higher.11
Structured Clinical Interview for DSM-IV Disorders
The SCID-I is a semi-structured interview for diagnos-
ing Axis I mental disorders according to DSM-IV crite-
ria.14 Interviewers, who received SCID-I training from 
an experienced psychiatrist, administered the SCID-I 
by telephone. A structured set of questions directed 
the interviewer in determining whether the symptoms 
(1) cannot be fully explained by a general medical 
condition, another mental disorder, or the effects of a 
substance; and (2) cause serious impairment in social, 
occupational, or other functioning. The interview-
ers had meetings every 2 weeks with the psychiatrist 
to secure the quality of the interviews. Agreement 
between a diagnosis gained from telephone and that 
from a live administration of the SCID-I is excellent.18
Statistical Analysis
Prevalence 
We analyzed the data with SAS 9 (SAS Institute, 
Cary, North Carolina). To calculate the prevalence 
of somatoform disorders in our population, we had to 
correct for using only the random sample of 40% of 
noncase participants with inverse probability weight-
ing.19 After correcting for this imbalance, all further 
calculations were performed with these balanced data, 
except for the calculation of the receiver operating 
characteristic (ROC) curve, the optimal cutoff point, 
and test-retest reliability.
Criterion Validity
We assessed the criterion validity of the ﬁ rst PHQ-15 
by calculating sensitivity and speciﬁ city using different 
cutoff values, which we visualized in a ROC curve. We 
assessed the utility for everyday practice by calculating 
positive and negative predictive values, using the opti-
mal cutoff value.
Internal Consistency 
A factor analysis of the PHQ-15 showed that 2 symp-
toms were only weakly associated with the factor: men-
strual problems (item-total correlation [ITC] 0.26) and 
sexual pain/problems (ITC 0.18). Kroenke et al found 
similar results.20 We therefore decided to exclude these 
symptoms from our analysis. Thus, the total score of 
the total 13-item PHQ-15 in our analysis ranged from 
0 to 26, compared with 0 to 30 when all 15 items of 
the PHQ-15 were scored.
Test-Retest Reliability 
We calculated the intraclass correlation coefﬁ cient to 
assess the test-retest consistency of the PHQ-15. Using 
the paired Student t test, we calculated the P value for 
the difference between the ﬁ rst and second PHQ-15 
outcomes. Next, we dichotomized the PHQ-15 out-
comes into cases and noncases and compared the ﬁ rst 
and the second PHQ-15 outcomes using the κ statistic, 
a measure of agreement that takes into account the 
inﬂ uence of chance. We measured the inﬂ uence of time 
on the ﬁ rst and second PHQ-15 scores using logistic 
regression analysis.
RESULTS
Thirty-ﬁ ve family physicians participated. In total, 
2,659 patients fulﬁ lled the criteria for mental health 
problems (MHP, n = 1,039), for frequently attend-
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ing their family physician (FA, 
n = 1,745), and for unexplained 
somatic complaints (USC, n = 183). 
There was overlap among the 
groups. The mean age was 45 years, 
and 60% were female (Figure 1).
Family physicians excluded 345 
patients from the study for the fol-
lowing reasons: death of the patient 
(7), being too old (13), schizophrenia 
or bipolar disease (43), inability to 
understand the Dutch or English lan-
guage (49), terminal illness or mental 
retardation (71), and serious illness 
(162). Additionally we excluded 167 
patients who were already known by 
their family physician to have major 
depressive disorder.
Of the remaining 2,147 patients 
eligible for PHQ-15 screening, 904 
(42%) patients returned the PHQ-
15 and gave informed consent: 68 
patients in the USC group, 344 in 
the MHP group, and 586 patients in 
the FA group (Figure 2). Consenting 
patients were slightly older (mean 
age 48 years).
Prevalence
Of the 904 patients, 602 (66%) patients had fewer 
than 3 severe somatic symptoms. The other 302 (33%) 
with 3 or more severe somatic symptoms (score of 6 
or higher), were considered to have a positive score. 
Patients in the MHP group had the lowest prevalence 
of a positive PHQ-15 at 31%, patients in the FA group 
had higher prevalence of a positive PHQ-15 at 35%, 
and patients in the USC group had the highest preva-
lence of a positive PHQ-15 at 63%. 
 Of the 426 patients who participated in the SCID-I 
interview, we diagnosed a somatoform disorder in 51. 
The MHP group had the lowest prevalence at 8.7%, the 
FA group a higher prevalence at 11%, and highest preva-
lence was in the USC group at 32%. Those 426 patients 
are a subgroup of our original population, which had 
a preplanned overrepresentation of patients with a 
positive outcome on the PHQ-15. After correction by 
inverse probability weighting for the 30% patient sam-
ple with negative PHQ-15 outcomes, the prevalence of 
somatoform disorders in our study population was 8.6%.
Sensitivity and Specifi city
We assessed the optimal physical symptom threshold 
for somatoform disorders with a ROC curve for the 
nonweighted sample (Figure 3). The optimal sum of 
Figure 1. Patient fl owchart.
Figure 2. Overview of the research population.
FA = frequent attenders; MHP = mental health problems; PHQ-15 = 15-symptom Patient Health Question-
naire; SCID-I = Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-IV 
Axis I disorders; USC = unexplained somatic complaints.
FA = frequent attenders; MHP = mental health problems; USC = unexplained 
somatic complaints.
2,147 Patients eligible for screening
1,243 Patients declined
Did not return full PHQ-15 or 
did not sign informed consent
904 Patients with informed consent
344 MHP, mean age 47 years, 67% female
586 FA, mean age 49 years, 57% female
68 USC, mean age 47 years, 82% female
302 Patients with PHQ-15 >6
302 Invited for SCID-I
602 Patients with PHQ-15 <6
262 Invited for SCID-I
340 Not invited for SCID-I
45 Patients SCID-I positive
174 Patients SCID-I negative
83 Declined or were not reached
6 Patients SCID-I positive
201 Patients SCID-I negative
55 Declined or were not reached
USC 43
MHP 274
FA 499
3
2
20
65
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sensitivity and speciﬁ city of the PHQ-15 is found at 
3 or more severe somatic symptoms (Table 1). The 
accuracy of the PHQ-15 is fair, with an area under the 
ROC curve of 0.76.
After correction with inverse probability weight-
ing, the sensitivity of the PHQ-15 (at a cutoff level 
of 3 or more severe somatic symptoms) was 78% and 
speciﬁ city was 71%, which yields a likelihood ratio for 
a positive test of 2.70 and a likelihood ratio for a nega-
tive test of 0.31. The positive predictive value shows 
that 21% of patients who have 3 
or more severe somatic symptoms 
on the PHQ-15 (score ≥6) will 
have a somatoform disorder. The 
negative predictive value of 97% 
indicates that only 3% of patients 
who have fewer than 3 severe 
somatic symptoms will have a 
somatoform disorder.
Reliability
We assessed test-retest reliability 
with the data from 355 patients 
who completed the second PHQ-
15 within 14 days after the ﬁ rst 
PHQ-15. This sample contains 
63% of the patients invited for 
the SCID-I (n = 564) and the 
second PHQ-15. The remaining 
37% did not participate in the 
SCID-I interview, nor did they 
complete the second PHQ-15.
By counting only the scores 
of 2, indicating severe somatic 
symptoms, the mean score of the 
ﬁ rst PHQ-15 was 6.1 points (SD, 
5.3); for the second PHQ-15, the 
mean score was 5.5 points (SD, 
5.3), a decrease of 0.6 points 
(P <.001). The intraclass correla-
tion coefﬁ cient was 0.83. Next, 
we dichotomized the outcome, 
that is, patients with 3 or more 
severe somatic symptoms were 
considered to have a positive 
PHQ-15 score and patients with 
fewer than 3 severe somatic 
symptoms were considered to 
have a negative PHQ-15 score. 
On the dichotomized outcome 
the percentage agreement 
between the ﬁ rst and second 
PHQ-15 score was 80%. The 
score changed from negative to 
positive in 6%, and from positive to negative in 14%. 
The κ coefﬁ cient was 0.60. A logistic regression analy-
sis with time as the independent variable found the fol-
lowing P values: P = .38 for negative PHQ-15 outcomes 
changing to positive, and P = .79 for positive PHQ-15 
outcomes changing to negative. So, there is no signiﬁ -
cant inﬂ uence of time on the difference in results from 
the ﬁ rst and second PHQ-15.
The internal consistency (Cronbach’s α) of the 
PHQ-15 is .80.
 Figure 3. Receiver operating characteristic curve of the PHQ-15.
Table 1. Using Symptom Thresholds to Predict Somatoform Disorders
Test Characteristics
Number of Severe Somatic Symptoms ≥
1 2 3a 4 5 6 7
Sensitivity 97.9 95.8 87.5 66.7 52.1 41.7 25.0
Specifi city 20.3 37.7 54.5 71.5 79.7 86.5 90.1
Negative predictive value 98.7 98.6 97.1 94.3 92.7 91.9 90.2
Positive predictive value 13.8 16.7 20.0 23.4 25.0 28.6 24.5
These data are calculated without inverse probability weighting.
a Optimal sum of sensitivity and specifi city.
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DISCUSSION
The sensitivity and speciﬁ city of the PHQ-15, as mea-
sured by the concordance with the SCID-I diagnosis 
of somatoform disorders, have been established in our 
primary care population as 78% and 71%, respectively, 
with a low positive predictive value and a high nega-
tive predictive value. The test-retest reliability is mod-
erate with a κ coefﬁ cient of 0.60.21 The prevalence of 
somatoform disorders differed signiﬁ cantly between 
the 3 high-risk groups. The patients identiﬁ ed by their 
family physicians as being in the USC group had by 
far the highest prevalence of severe somatic symptoms. 
Diagnosis of somatoform disorders was 3 times more 
likely in this group than in the MHP and FA groups.
Strengths and Limitations
We excluded patients who had a diagnosis of depres-
sion at baseline for both research and clinical reasons. 
Often patients with depression have somatic com-
plaints that could ﬁ t the diagnosis of a somatoform 
disorder, but usually their depression better accounts 
for those complaints. The PHQ-15 measures symp-
toms regardless of underlying disorders. In contrast, 
the SCID-I will lead to a diagnosis of somatoform 
disorders only if complaints are not accounted for by 
another mental disorder. Accordingly, the relatively 
low prevalence of somatoform disorders in our study 
population (8.6%) might be because we excluded the 
patients with known depression at baseline.
The suitability of the SCID-I to diagnose somato-
form disorders has been criticized. The best-estimate 
diagnosis is considered to be more accurate in this 
respect.22 The best-estimate diagnosis consists of longi-
tudinal assessment, done by expert diagnosticians, using 
all available patient data, such as obtained from family 
informants, review of medical records, and observations 
of clinical staff. Although this standard is appealing, it 
is often not used in research practice, so for practical 
reasons, we have chosen to use the SCID-I.
We found a high internal consistency (α = .80), 
which replicates the ﬁ ndings of Kroenke et al (α = .80) 
and Interian et al (α = .79).4,13 Interian et al measured 
the convergent validity of the PHQ-15 with the Com-
posite International Diagnostic Interview symptom 
count in patients with moderate to severe somatization. 
They found a signiﬁ cantly lower validity in the His-
panic population. Their results are difﬁ cult to compare 
with ours because we used a different validation instru-
ment, and we used it in a mainly Dutch population.
For the diagnosis of a somatoform disorder, the 
complaints are necessarily medically unexplained. Such 
a diagnosis requires clinical judgment, which a question-
naire cannot provide. One might expect that patients 
with known physical disorders have many somatic 
symptoms and therefore high scores on the PHQ-15. In 
earlier research, however, only a weak correlation was 
found between the number of physical disorders and the 
number of somatic symptoms.4 Total symptom counts, 
including unexplained and explained, have been proved 
to be prognostic for somatoform disorders.20,23
As we excluded patients with mental retardation 
and patients having difﬁ culties with Dutch or English 
language, all included patients were able to read and 
understand the questions. We performed our research in 
clinically relevant family practice subgroups during rou-
tine practice. Patients who frequently attend, patients 
who have mental health problems, and patients with 
unexplained symptoms are at risk for somatization and 
thus for unnecessary medical procedures and problem-
atic doctor-patient relationships. With this procedure we 
increased the chance of detecting a meaningful result. 
Moreover, we tested the instrument in the subgroup of 
patients for whom family physicians are likely to use it.
The response to our ﬁ rst PHQ-15 measurement was 
low (42%). Usually around 50% of subjects respond to 
questionnaires. We did not ask patients only to return 
the questionnaire, however; we also asked for their 
participation within the whole project, including treat-
ment in a trial setting. We assume that the patients, 
especially patients with mental health problems, might 
have been less willing to return the PHQ-15 because 
they did not want to take part in the trial.
This study is the ﬁ rst to examine the test-retest 
validity of the PHQ-15, which we found to be moder-
ate. Although we expected time between tests to affect 
the outcome, we could not ﬁ nd an inﬂ uence of time on 
test-retest reliability. The decrease in PHQ-15 scores 
between the test and the retest could be explained by 
both the natural course of symptoms and by regression 
toward the mean.
Implications for Research and Clinical Practice
The PHQ-15 has proved to be a valid and moderately 
reliable instrument for recognition of somatoform 
disorders in our primary care study population. For 
implementation into clinical practice, one should real-
ize that we excluded patients with a depression. The 
negative predictive value of the PHQ-15 (97%) offers a 
considerable advantage in family medicine, where inci-
dences are usually low. This short questionnaire can be 
used to exclude the diagnosis of a somatoform disorder 
in most patients. For a small group of patients, further 
discussion of a patient’s symptoms will be necessary 
to draw ﬁ rm conclusions. This course ﬁ ts well into the 
primary care process. Taking into consideration the 
complex nature of somatization, the PHQ-15 might 
bring us the closest we can get to objectively identify-
ing patients at high risk for somatoform disorders.
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